Resistance of targeted therapies excluding antibodies for lymphomas. (2018)

• Record Type: Book
• Further Information: Note: Andrés J.M. Ferreri, editor.
• Editors: Ferreri, Andrés J. M
• Contents: Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Series Editor Biography; Acknowledgements; Editor's Biography; Preface; Contents; BTK Inhibitors: Focus on Ibrutinib and Similar Agents; Introduction; Ibrutinib Biochemical Structure, PK, PD, Routes and Doses; Ibrutinib: Efficacy and Safety Clinical Data; Resistance to BTK Inhibitors; Clinical Studies on Resistance Mechanisms in CLL; Prognosis After Disease Progression and Transformation in CLL; Resistance Mechanisms in MCL; Clinical Trials and Resistance Mechanisms in Waldenström's Macroglobulinemia. Other BTK InhibitorsConclusion; References; BCL2 Inhibitors: Insights into Resistance; Introduction; BCL2 and Cancer; BH3 Mimetics; ABT-737; Navitoclax; Venetoclax; Biochemistry; Pre-clinical Data; Administration and Pharmacokinetics; Clinical Outcomes; Clinical Effect of Resistance; Molecular Mechanisms of Resistance; Conclusion; References; Proteasome Inhibitors with a Focus on Bortezomib; Introduction; The Ubiquitin Proteasome System; Proteasome Inhibitors: Mechanism of Anti-tumor Effect; Cell Intrinsic Mechanisms of Resistance; Proteasome Subunit Mutations; Efflux Pumps; Autophagy. Plasmacytic DifferentiationProteasome Subunit Expression; BCL-2; Cell Extrinsic Mechanisms of Resistance; Interleukin-6; The Hedgehog Pathway; Overcoming Bortezomib Resistance; Targeting the Immature Plasma Cell; Differentiation Induction; Synergistically Activating the Unfolded Protein Response; BCL-2 Inhibition; Conclusion; References; IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms; Introduction; Non-Hodgkin's Lymphoma; Lenalidomide for the Treatment of Lymphoma. Structure and Mechanism of ActionToxicities; Other Insights from Preclinical Models; Clinical Indications and Data; Predictive Markers for Lenalidomide in Patients with Lymphoma; Molecular Mechanisms of Resistance; Future Directions; References; mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents; Introduction: Rapamycin and Rapalogs History; The mTOR Pathway and mTOR Inhibitors; Pharmacokinetics of Rapalogs; Toxicity; Pneumonitis; Metabolic Adverse Events; Hematological Toxicities; mTOR Inhibitors Associated Stomatitis (mIAS); Mechanisms of Resistance; Mutations of mTOR. Genetic and Functional HeterogeneityAlternative Proliferation Pathways; Molecular Mechanisms of mTOR Activation in Lymphomas; Summary of Clinical Trials; Temsirolimus; Everolimus; Ridaforolimus; Second Generation mTOR Inhibitors; Summary; References; Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents; The JAK/STAT Intracellular Signaling Pathway; Deregulated JAK/STAT Signaling in Lymphomagenesis; Mutations that Alter JAK2 Copy Number but Not Its Coding Sequence; Mutations that Directly Alter the JAK Family Members; Mutations that Target the STAT Family Members.
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2018
• Extent: 1 online resource (xiii, 138 pages), illustrations (some color)
• Subjects: 616.99/446061; Medicine; Lymphomas -- Chemotherapy; Drug targeting; HEALTH & FITNESS -- Diseases -- General; MEDICAL -- Clinical Medicine; MEDICAL -- Diseases; MEDICAL -- Evidence-Based Medicine; MEDICAL -- Internal Medicine; Drug targeting; Lymphomas -- Chemotherapy; Science -- Life Sciences -- Biology -- Molecular Biology; Medical research; Oncology; Medical -- Oncology; Oncology; Electronic books
• Languages: English
• ISBNs: 9783319751849; 3319751840
• Related ISBNs: 9783319751832; 3319751832
• Notes: Note: Online resource; title from PDF title page (SpringerLink, viewed April 11, 2018).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.